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Vasoactive intestinal peptide (VIP) plays important roles in many biological functions, such as, stimulation of
contractility in the heart, vasodilation, promoting neuroendocrine-immune communication, lowering arterial blood
pressure, and anti-inflammatory and immune-modulatory activity. Osteoarthritis (OA) is a chronic and degenerative
bone disease, which is one of the most common causes of disability and most common in both sexes as people
become older. Interestingly VIP can prevent chronic cartilage damage and joint remodeling. This review article
provides update information on the association of VIP and OA and its treatment. Evidences suggest that VIP is
down-regulated in synovial fluid of OA, and VIP down-regulation leads to increase in the production of pro-
inflammatory cytokines that might contribute to the pathogenesis of OA; however contradictory reports also exist
suggesting that accumulation of VIP in joints can also contribute OA. A number of studies indicated that up-
regulation of VIP can counteract the action of pro-inflammatory stimuli and alleviate the pain in OA. More clinical
investigations are necessary to determine the biology of VIP and its therapeutic potential in OA that might
represent the future standards of care for OA.
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The vasoactive intestinal peptide (VIP) also known as
the vasoactive intestinal polypeptide is a neuropeptide
that belongs to a glucagon/secretin superfamily, the lig-
and of class II G protein-coupled receptors [1, 2]. It was
initially reported to be expressed in lung and small intes-
tine tissue; however, currently it is also described in neu-
rons of central nervous system (CNS) [3, 4]. Beside the
neuronal source, VIP is also expressed and released from
endocrine organs (such as heart, thyroid, kidney and
gastrointestinal tracts) and immune organs (such as
spleen, thymus, bone marrow and lymph nodes) [5]. VIP
plays essential roles in a broad spectrum of biological* Correspondence: liyusheng0731@sina.com; luowei0928@126.com
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vasodilation, promotes neuroendocrine-immune com-
munication, increases glycogenolysis and lowers arterial
blood pressure [1, 3]. VIP displays potent anti-
inflammatory and immune-modulatory activity and
modulation of VIP level has considered being a potential
candidate for treatment of inflammatory and auto-
immune diseases including acute pancreatitis, septic
shock, inflammatory bowel disease, lipopolysaccharide
(LPS)-induced acute inflammation and arthritis [6, 7].
Osteoarthritis (OA) is a chronic and degenerative dis-
ease that results from the breakdown of articular cartil-
age components (particularly type II collagen and
cartilage specific proteoglycans) and extensive remodel-
ing of subchondral bone leading to synovitis as well as
osteophyte formation [8, 9]. OA is the most common
form of arthritis with disease of near the ends of thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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weight bearing, mobility and normal daily activities [10].
It is one of the most common causes of disability and
most common in both sexes as people become older.
Among adults in the age of over 60 years, the prevalence
of OA is approximately 10 % in men and 13 % in women
[11]. The exact cause of OA is unclear. The etiology of
OA is complex and multi-factorial including age, sex,
and body weight, genetic, biological and biomechanical
components. OA is believed to be caused by previous
joint injury, abnormal limb development or mechanical
stress on the joint [12, 13]. The most common clinical
symptoms of OA are joint pain, swelling, decreased
range of motion and stiffness. The joint pain is mainly
due to the inflammation effects and the sensitization of
neurobiological processes and further stimulation cas-
cade of inflammation responses. During inflammation,
mechanical stimuli sensitize joint nerves the actions of
certain neuropeptides, eicosanoids, proteinase-activated
receptors and ion channel ligands. Usually the inflamma-
tory neuropeptides substance P, calcitonin gene-related
peptide, as well as VIP, have all been reported to be
immunolocalized in joint tissues and their levels are in-
creased in arthritis [14].
Treatment of OA includes exercise, lifestyle modifica-
tion and pain medications. The treatment of OA is still
restricted to analgesics which have some undesirable
and hazardous side effects. If the conventional manage-
ment is ineffective and pain interferes with normal life,
joint replacement surgery may be recommended. Evi-
dence supports that joint replacement is both clinically
effective and cost-effective; however, the functional and
clinical outcomes can be poor [9, 12]. Therefore, alter-
native therapeutics is urgently needed that could im-
prove the survival rate and quality of life of OA
patients. A better understanding of the pathological
mechanisms by which it promotes initiation and
maintenance of joint pain in OA may help to identify
the more effective targets to counteract the debilitat-
ing symptoms of OA [15, 16].
Evidence suggests that VIP is shown to prevent
chronic cartilage damage and joint remodeling [7]. It
shows the therapeutic function in rheumatoid arthritis
(RA); however, the protective function of VIP in the
progression of OA is not fully explained [2, 17]. In
this review, we have focused on the association of
VIP in the development and progression of OA and
the potential effects of VIP as a therapeutic agent for
the treatment of OA.
Review
Basic structure and functions of VIP
VIP is a widely distributed neuropeptide that functions
as a neurotransmitter or neuromodulator in manyorgans and tissues. It contains 28 amino acid residues
and in humans, it is encoded by the VIP gene [1, 18].
The gene is approximately 9 kb long and contains 7
exons, each encoding a distinct functional domain. Exon
1 consists of the 5’-untranslated region of the mRNA,
exon 2 encodes a putative signal peptide, exon 3 encodes
an N-terminal peptide, exon 4 encodes PHM (peptide
with N-terminal histidine and C-terminal methionine
amide), exon 5 encodes VIP, exon 6 encodes the C-
terminal peptide and exon 7 consists of the 3’-untrans-
lated region of the mRNA [4, 19].
VIP consists of 3 receptors: VIP receptor type 1
(VPAC1), VIP receptor type 2 (VPAC2) and pituitary ad-
enylate cyclase-activating polypeptide (PACAP) type 1
(PAC1) receptor [20, 21]. These receptors belong to fam-
ily 2 of the G protein–coupled receptors and elicit re-
markable anti-inflammatory and immune-modulatory
properties by up-regulating cyclic adenosine 5’-phos-
phate (cAMP), adenylate cyclase and phospholipase C
(PLC) [2, 9]. VPAC receptors are expressed in macro-
phages as well as in lymphocytes among which VPAC1
is thought to be the major receptor type present during
early culture period while VPAC2 is expressed relatively
late during macrophage/monocyte activation as an indu-
cible receptor after T cell receptor triggering or LPS
stimulation. VPAC receptors are expressed in macro-
phages as well as in lymphocytes among which VPAC1
is thought to be the major receptor type present during
early culture period while VPAC2 is expressed relatively
late during macrophage/monocyte activation as an indu-
cible receptor after T cell receptor triggering or LPS
stimulation. PAC1 was found to be expressed in cells of
the macrophage/monocyte lineage. The differential ex-
pression of VIP receptors (VPAC1 and VPAC2) in arth-
ritis is also reported. The expression of VPAC1 mRNA is
significantly decreased while the expression of VPAC2
mRNA is increased in arthritic fibroblast-like synovio-
cytes (FLS) [5, 17].
VIP is synthesized from a precursor molecule (prepro-
VIP) which is metabolized by a signal peptidase in the
endoplasmic reticulum to yield pro-VIP. The pro-VIP is
cleaved by prohormone convertases to form VIP-GKR
(prepro-VIP125–155) which is then cleaved by
carboxypeptidase-B-like enzymes to VIP-G (glycine-ex-
tended VIP). The VIP-G can then be metabolized by
PAM enzymes to VIP [4].
VIP has pleiotropic effects as a neurotransmitter, im-
mune regulator, vasodilator and secretagogue. In CNS,
VIP has been shown to have neurotrophic effects that
affect learning and behavior capacity [5]. VIP regulates
bone metabolism, circadian rhythms and embryonic de-
velopment, and plays an important role as immune
modulator [5]. In focus on controlling joint inflamma-
tion, VIP plays dual role, as it functions as a macrophage
Fig. 1 Negative role of VIP in osteoarthritis pathogenesis. The
expression of VIP is down-regulated in synovial fluid of OA and
down-regulation of VIP stimulates the production of pro-inflammatory
cytokines that might contribute to the pathogenesis of OA by
developing pain, joint inflammation and cartilage degradation
[16, 25, 33]
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pro-inflammatory cytokines (IL-1, IL-6, IL-12) and tumor
necrosis factor-α (TNF-α), while stimulates the produc-
tion of anti-inflammatory cytokines such as IL-4, IL-10,
IL-13 and insulin-like growth factor 1 (IGF-1) [4, 22]. It
shifts the Th1 (pro-inflammatory)/Th2 (anti-inflamma-
tory) balance by promoting TH2 differentiation and inhi-
biting TH1 responses and shows a protective effect on
joint swelling, and destruction of cartilage and bone
[7, 23]. VIP also modulates IL-22R1 expression and
prevents the contribution of FLS in RA to counterbal-
ance IL-22 effects on FLS behavior [24]. VIP also has
significant effects on the cardiovascular system, where
it contributes to the regulation of normal coronary
vasomotor tone, increases the epicardial coronary ar-
tery cross-sectional area, decreases coronary vascular
resistance and significantly increases coronary artery
blood flow and vasodilation [18]. As a secretagogue,
VIP induces release of various types of hormones in-
cluding prolactin, luteinizing hormone and growth
hormone from the pituitary, and regulates the release
of insulin and glucagon in the pancreas [5].
Association of VIP with OA
The association of VIP is more clearly detected in RA
but the exact role of VIP in the pathogenesis of OA re-
mains largely unknown [8]. In most of the studies, VIP
functions in joint protection were performed in RA
model; however, the protective function in the progres-
sion of OA is uncertain. Jiang et al. [2] suggested in their
study that VIP may play a protective role in progression
of OA just like in RA, as the expression of VIP in syn-
ovial fluid and articular cartilage from patients with OA
is negatively associated with progressive joint damage
and disease sevrity.
VIP is reported to be localized in postganglionic sym-
pathetic and sensory nerve fibres that are in close prox-
imity to the synovial fluid and serum of arthritis
patients. FLS are abundant synovial cell populations that
play regulatory roles in inflammation and joint destruc-
tion. Synovial thickening is frequently present in OA
and uniquely associated with the severity of knee pain
[25]. VIP expression is down-regulated in synovial fluid
and articular cartilage of OA patients, and down-
regulation of this endogenous VIP might contribute to
the pathogenesis of OA by providing contribution sig-
nificantly to the development of pain, joint inflammation
and cartilage degradation (Fig. 1) [2, 17]. In OA FLS, en-
dogenous VIP is found at a much lower level. Lower
level of endogenous VIP stimulates the formation of
various catabolic mediators including pro-inflammatory
cytokines, nitric oxide and prostaglandin E2, and con-
tributes to the pathogenesis of OA by altering the bal-
ance of cartilage matrix degradation and repair [26]. VIPalso stimulates nuclear translocation of cytokine tran-
scription factors (NFkB and c-JUN) and subsequent
TNF-α production by human monocytes through the re-
duction of LPS, and up-regulation of the TLR-2 and
TLR-4 Toll-like receptors [27–29]. VIP suppresses the
phosphorylation of IKKβ, prevents degradation of the
IkBα and inhibits NFkB binding activity, thereby, modu-
lates cell function [30]. VIP impairs the development of
self reactive Th1 and Th17 cells, activates macrophages
and neutrophils as well as increases the production of
pro-inflammatory and joint destruction mediators such
as CCL2 (MCP-1, monocyte chemotactic protein 1),
CXCL8 [interleukin (IL)-8], IL-6, interferon-β (IFN-β)
and IFN regulatory factor 3 (IRF-3) in OA FLS [31–33].
The expression of the urokinase plasminogen activator
(uPA) system components is increased in OA. In the
presence of lower level of VIP, IL-1β as inflammatory
cytokine, and Fn fragments derived from cartilage de-
struction stimulated uPA system and promotes the per-
petuation of the destructive cascade in joint through the
production of matrix metalloproteinases-9 (MMP-9) and
metalloproteinases-13 (MMP-13) in OA-FLS [34–36].
One contradictory study has suggested that up-
regulation of VIP in arthritic knees induces synovial
hyperaemia via VPAC receptors located within the knee
joint and sensitization of joint afferents leading to
Jiang et al. Journal of Biomedical Science  (2016) 23:63 Page 4 of 6nociception. The mechanism by which VIP exerts its
pro-nociceptive effects includes the enhanced produc-
tion of cAMP and enhanced protein kinase A activity
through the stimulation of adenylyl cyclase [37]. VIP is
released into OA knee joints and sensitizes afferent
nerve fibres, enhanced firing rate during joint movement
and reduced mechanical threshold after induction of OA
[38]. It is reported that stimulation of synovial VPAC re-
ceptors by VIP in OA knees increases the production of
IL-1β, IL-6 and TNF-α which in turn sensitize joint af-
ferent nerve terminals leading to induce mechanosensi-
tivity and pain [9]. Subsequent accumulation of VIP in
the joint down-regulates the VPAC receptor and the
vasodilatatory effect of VIP is lost during acute knee
joint inflammation. VIP-containing nerves have the po-
tential to involve in articular vasoregulation. VIP-
induced vasomotor control is found to be altered in
arthritis [39, 40]. Mast cells are involved in modulating
tissue inflammation and activation of these immune cells
results in cellular degranulation. The inflammatory me-
diators are released into the extracellular environment
contributing vascular dysfunction and alter the homeo-
static mechanisms that regulate synovial blood flow in
OA. As synovial fluid provides nutrition to articular car-
tilage, loss of vasomotor control of the synovial micro-
circulation could contribute to the degenerative changes
in OA (Fig. 2) [41, 42].
VIP level is actually down-regulated in both synovial
fluid and areticular cartilage, and the level is negatively
correlated with disease severity [2]. However, studies
found that extremely higher level of VIP accumulationFig. 2 Positive role of VIP in osteoarthritis pathogenesis. VIP is released into
down-regulates the VPAC receptor. Up-regulation of VIP increases the prod
nerve fibres leading to the vascular dysfunction and degenerative changesin joint is responsible for receptor desensitization, and
in a different mechanism, VIP contributes the produc-
tion of pro-inflammatory cytokines. Thus, down-
regulated VIP in synovial fluid and up-regulated VIP in
joint are responsible for OA pathogenesis.
Can VIP be used as target in OA?
OA is the most common form of arthritis and has be-
come a big threat for normal healthy life. The conven-
tional therapy of OA is still unsatisfactory as these are
highly expensive and cannot cure totally. Effective pre-
vention and therapeutic treatment of OA will require
the identification of appropriate mediators of joint pain
and articular cartilage degradation [43]. VIP, a natural
protein with well-known physiological effects is being
considered as a potential therapeutic agent and a prom-
ising candidate for the treatment of OA [8, 32]. It is re-
ported that pro-inflammatory cytokines stimulate the
production of matrix metalloproteinase and administra-
tion of VIP is reported to counteract the action of these
pro-inflammatory stimuli and reduces the constitutive
expression of MMP-9 and MMP-13, thereby, alleviating
pain in OA [8, 34]. Pérez-García et al. [44] analyzed the
effect of VIP on the corticotropin-releasing factor (CRF)
system and urocortins (UCN1, UCN2, UCN3) in human
OA synovial fibroblasts. VIP treatment in OA FLS
causes a significant increase of the potential anti-
inflammatory mediators (UCN2 and UCN3) through the
modulation of the expression of CRF system that indi-
cates the anti-inflammatory function and therapeutic po-
tential of VIP in OA. In one study, Delgado et al. [7]OA knee joints and subsequent accumulation of VIP in the joint
uction of pro-inflammatory cytokines which in turn sensitizes afferent
in OA [37, 38, 40]
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joints shown completely ameliorate collagen destruction
and joint remodeling in a murine model of collagen-
induced arthritis.
However, some contradictory studies reported that
VIP is released into OA knee joints and potentially con-
tributing to joint pain [9, 38, 45], and VIP inhibition
may be a useful means of controlling joint pain. Treat-
ment of OA knees with a VPAC receptor antagonist
VIP6-28 significantly inhibits the sensitizing effect of
VIP, decreases afferent firing rate and reduces mechano-
nociception in OA joints [9]. There is a lack of clinical
evidence which may support that targeting VIP is suc-
cessful in OA treatment. More investigations including
in vivo studies or VIP knockout animal model are neces-
sary to define the signaling events induced by VIP and
its therapeutic potential in OA.Conclusion
OA is a chronic and debilitating disease among the eld-
erly people. It is a complex and painful disease whose
progression is associated with a chronic synovitis, deg-
radation of articular cartilage, remodeling of subchon-
dral bone and osteophyte formation. Currently, there are
no satisfying drugs and agents for treating OA. Only
management is possible to alleviate its symptoms. Des-
pite the development of modern medical science, very
little is known about the factors responsible for the
pathogenesis of OA. Proper investigation of the modu-
lating factors that might alter the incident of pain may
improve the potential therapy for OA. VIP is reported as
an anti-inflammatory and immune-modulatory peptide
that has considered being a potential candidate for treat-
ment of inflammatory and autoimmune diseases through
down-regulation of inflammatory cytokines and media-
tors. However, only a few experiments have been con-
ducted to demonstrate the potential value of VIP in the
treatment of OA. More investigations are necessary to
determine the biology of VIP and its therapeutic poten-
tial in OA that might represent the future standards of
care for OA.
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